TGA investigates bowel obstruction risk with semaglutide

The US medicine regulator updated the product information for Ozempic last month to include a warning about potential risk of ileus.

The TGA is investigating reports of intestinal obstruction in patients using semaglutide and may consider updating the product information to include a warning about ileus. 

The watchdog said it had received four reports of adverse gastrointestinal events linked with semaglutide (Ozempic) to date.